Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Atrium integrates Trophic Canada

This article was originally published in The Tan Sheet

Executive Summary

With its integration of Trophic Canada completed in the second quarter, Atrium Innovations reports 17.3 percent revenue growth to $85.2 million. Atrium bought Trophic for $11 million to bolster its Canadian operations through the Trophic and Wild Rose supplement brands (1"The Tan Sheet" April 12, 2010, In Brief). The 2009 Garden of Life acquisition also boosted sales and Atrium CEO Pierre Fitzgibbon said in an Aug. 12 release the Quebec City firm still is assessing "multiple opportunities for acquisitions." Atrium's net earnings grew 11.4 percent to $12.5 million in the three months ended June 30, and diluted net earnings per share increased to 38 cents from 34 cents

You may also be interested in...



Interview: Health & Wellness Investment Bank PCGA Prioritizes Supplement Innovation, Quality

Investment capital has followed the flood of consumer interest in the natural health and wellness market. Partnership Capital Growth Advisors was founded as an investment bank and financial advisor in 2005 to focus precisely on the "healthy, active and sustainable living" segment.

Atrium Innovations acquires Trophic Canada

Atrium Innovations' $11 million acquisition of the vitamin, mineral and supplement maker and distributor Trophic Canada gives the marketer "a stronger and complementary foothold" in the Canadian market. Trophic's two brands, Trophic and Wild Rose, include 150 products and sell approximately $7.5 million annually, primarily in specialized health food stores, according to Atrium's March 18 release. Atrium entered health food stores last September with the acquisition of Garden of Life (1"The Tan Sheet" Sept. 22, 2009). Before that it acquired enzyme manufacturer Enyzm-Arzeimittel-Berlin (2"The Tan Sheet" May 25, 2009, In Brief)

Executives On The Move: Allergy Therapeutics, Solid Biosciences and More

Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel